TG Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. 

CEO
Michael Sean Weiss
CEOMichael Sean Weiss
Employees
399
Employees399
Headquarters
Morrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded
1993
Founded1993
Employees
399
Employees399

TGTX Key Statistics

Market cap
6.00B
Market cap6.00B
Price-Earnings ratio
13.66
Price-Earnings ratio13.66
Dividend yield
Dividend yield
Average volume
1.48M
Average volume1.48M
High today
$39.31
High today$39.31
Low today
$38.55
Low today$38.55
Open price
$39.00
Open price$39.00
Volume
310.00K
Volume310.00K
52 Week high
$44.65
52 Week high$44.65
52 Week low
$25.28
52 Week low$25.28

Stock Snapshot

TG Therapeutics(TGTX) stock is priced at $39.19, giving the company a market capitalization of 6B. It carries a P/E multiple of 13.66.

As of 2026-05-28, TG Therapeutics(TGTX) stock has fluctuated between $38.55 and $39.31. The current price stands at $39.19, placing the stock +1.7% above today's low and -0.3% off the high.

TG Therapeutics(TGTX) shares are trading with a volume of 310K, against a daily average of 1.48M.

During the past year, TG Therapeutics(TGTX) stock moved between $25.28 at its lowest and $44.65 at its peak.

During the past year, TG Therapeutics(TGTX) stock moved between $25.28 at its lowest and $44.65 at its peak.

TGTX News

TipRanks 19h
TG Therapeutics reports positive Phase 3 ENHANCE trial results

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 1d
TG Therapeutics reports ENHANCE trial meets primary endpoint

TG Therapeutics (TGTX) announced topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regi...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
12.5%
Sell
12.5%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.